

May 30, 1974

Lyle Miller, M. D.
Eastern Pennsylvania Psychiatric Institute
Henry Avenue and Abbottsford Road
Philadelphia, Pennsylvania

Dear Lyle:

I put your letter of April 18 aside as I was trying to summarize the peptide literature for a meeting of the ECDEU. I am enclosing a copy of that summary for your information.

The proposed outline of a study of 'ACTH 4-10 and Attention' is interesting and as soon as you have the protocol in better shape, I would have little difficulty in processing it. One question is to the dosage. Is not 10 mg low? Why not 30 mg?

Regarding your comment on our OI-63 data, we have studied the changes in alertness with placebo in our subjects, and do find that it decreases in time. For some substances, alertness is maintained, and this is defined as a drug effect. In the OI-63 study, we did note the change in alertness, but were not sure that the change was sufficient to be a drug effect. We attempted to re-examine at higher doses, and may have ignored a finding, since a re-examination shows the same changes at higher doses. Thanks.

I look forward to reading the protocol of the suggested study, particularly the selection of the CPT task.

My best regards.

Sincerely yours,

Max Fink, M. D.
Professor of Psychiatry

MF:ed
Encl.